|
|
|
28.07.26 - 12:06
|
Invitation to Detection Technology′s webcast on half-yearly report (Cision)
|
|
|
Detection Technology Plc press release 28 July 2026 at 13:00 (EEST)
Detection Technology will publish its half-yearly report on Thursday 6 August 2026 at 9:00 (EEST). Hannu Martola, the President and CEO of Detection Technology, will present the Q2 and January–June 2026 financial performance and events to analysts, investors, and media at a webcast to be held on the same day. The live webcast in English will begin at 13:00 (EEST).
A link to the webcast is available on the company's website (investors, webcasts (https://www.deetee.com/reports-and-presentations/webcasts/)). A recording...
|
|
|
|
|
|
|
|
|
17.07.26 - 13:01
|
ROUNDUP: Orion Q2 Profit Rises; Revises Outlook (AFX)
|
|
|
HELSINKI (dpa-AFX) - (Adds Outlook)For the full year, Orion Oyj (0M2N.L) now expects operating profit of EUR 650 million to EUR 750 million, compared with the previous expectation of EUR 600 milli......
|
|
|
17.07.26 - 12:00
|
Orion Oyj Reveals Advance In Q2 Income (AFX)
|
|
|
HELSINKI (dpa-AFX) - Orion Oyj (0M2N.L) reported earnings for its second quarter that Increased, from last yearThe company's bottom line came in at EUR140.2 million, or EUR1 per share. This compar......
|
|
|
|
|
|
|
|
|
|
|
07.07.26 - 18:00
|
Correction: The Board of Directors of Bioretec Ltd resolved on a new stock option plan (Cision)
|
|
|
Bioretec Ltd Company Announcement 7 July 2026 at 6:55 p.m. EEST
Bioretec Ltd corrects its release concerning the decisions of its Board of Directors on a new stock option plan on 1 June 2026 at 7.05 p.m. EEST. The split between the stock options marked with the symbol 2026A and 2026B was incorrect.
Incorrect information:
Number of stock options marked with the symbol 2026A: 96,059,674
Number of stock options marked with the symbol 2026B: 86,911,133
Correct information:
Number of stock options marked with the symbol 2026A: 97,584,430
Number of...
|
|
|
|
|
02.07.26 - 13:30
|
Inside information: Chief Financial Officer Tuukka Paavola will leave the company (Cision)
|
|
|
Bioretec Ltd, Inside Information, 2 July 2026 at 14.30 EEST
Bioretec Ltd and Tuukka Paavola have mutually agreed that Paavola will not continue in his position. Paavola will leave his role with immediate effect. The duties of the Chief Financial Officer will be assumed on an interim basis by Controller Anna-Mari Venola until a new Chief Financial Officer is appointed.
Bioretec will immediately initiate the recruitment process for a new Chief Financial Officer.
Paavola started in the position on January 20, 2026.
Bioretec thanks Tuukka Paavola for his contribution as Chief...
|
|
|
30.06.26 - 14:42
|
Terveystalo Plc′s Extraordinary General Meeting has approved the proposed resolution related to the acquisition of Silmäasema Oy (Cision)
|
|
|
Terveystalo Plc, Stock exchange release, 30 June 2026 15:40 p.m. EEST
Terveystalo Plc's Extraordinary General Meeting has approved the proposed resolution related to the acquisition of Silmäasema Oy
Terveystalo Plc's ("Terveystalo" or the "Company") Extraordinary General Meeting was held on Tuesday 30 June 2026 as a real-time virtual meeting in accordance with Chapter 5, Section 16, Subsection 3 of the Finnish Companies Act. The General Meeting approved the proposed authorisation to issue shares in connection with the acquisition of Silmäasema Oy.
The Company announced on 8 June...
|
|
|
|
|
|
|
|
|
18.06.26 - 16:36
|
Inside Information: Optomed receives a large order in the US (Cision)
|
|
|
Optomed Plc Stock Exchange Release 18 June 2026 at 17.30, Helsinki
Inside Information: Optomed receives a large order in the US
Optomed has received an order of approximately USD 2.1 million (EUR 1.8 million) from a US screening service provider and distributor in the US. The order is for traditional capital sales and does not include AI service or a recurring revenue component.
The order is expected to have a positive effect on the Devices segment for the second half of the year.
Outlook unchanged: Optomed expects its full year 2026 revenue to grow compared to 2025....
|
|
|
|
|
17.06.26 - 15:06
|
Bioretec appoints Conan Cavanagh as Head of Research & Development and member of the Management Team (Cision)
|
|
|
Bioretec Ltd | Press Release | 17 June 2026 at 16:00 EEST
Bioretec Ltd, a pioneer in absorbable orthopedic implants, has appointed Conan Cavanagh as Head of Research & Development and as a member of the management team as of 1 September 2026. Cavanagh will report directly to CEO Sarah van Hellenberg Hubar-Fisher.
Conan Cavanagh has over 25 years of experience in the development of medical devices, biomaterials, and product commercialization. He currently serves as Chief Operating Officer and Head of Research & Development at HidraMed Solutions. Previously, among other positions,...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
